An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.
Public ClinicalTrials.gov record NCT04660812. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating The Efficacy and Safety of AB928 Based Treatment Combinations in Patients With Metastatic Colorectal Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This randomized phase 1b/2 open-label study will evaluate the antitumour activity and safety of etrumadenant (AB928) treatment combinations in participants with metastatic colorectal cancer.
Study identification
- NCT ID
- NCT04660812
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 227 participants
Conditions and interventions
Conditions
Interventions
- AB680 Drug
- Etrumadenant Drug
- Zimberelimab Drug
- Bevacizumab Drug
- m-FOLFOX-6 regimen Drug
- Regorafenib Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 10, 2021 (Actual)
- Primary completion
- Sep 5, 2025 (Actual)
- Completion
- Sep 5, 2025 (Actual)
- Last update posted
- Oct 20, 2025
2021 – 2025
United States locations
- U.S. sites
- 17
- U.S. states
- 14
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arizona Clinical Research Center Inc | Tucson | Arizona | 85715 | — |
| City of Hope Comprehensive Cancer Center | Duarte | California | 91010 | — |
| UCLA Hematology Oncology | Santa Monica | California | 90404 | — |
| Yale Cancer Center | New Haven | Connecticut | 06510 | — |
| Sibley Memorial Hospital | Washington D.C. | District of Columbia | 20016-2633 | — |
| Winship Cancer Institute at Emory University | Atlanta | Georgia | 30322 | — |
| Ochsner Medical Center (OMC) | New Orleans | Louisiana | 70121 | — |
| American Oncology Partners of Maryland PA | Bethesda | Maryland | 20817 | — |
| Washington University School of Medicine | St Louis | Missouri | 63110 | — |
| Comprehensive Cancer Centers Of Nevada | Las Vegas | Nevada | 89169 | — |
| NYU Langone Medical Center - NYU Medical Oncology Associates | New York | New York | 10016 | — |
| New York-Presbyterian Hospital-Columbia University Medical Center | New York | New York | 10032 | — |
| Prisma Health-Upstate | Greenville | South Carolina | 29605 | — |
| Vanderbilt-Ingram Cancer Center | Nashville | Tennessee | 37203 | — |
| Sarah Cannon Research Institute | Nashville | Tennessee | 37232 | — |
| The University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| University of Wisconsin School of Medicine | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 27 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04660812, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 20, 2025 · Synced Oct 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04660812 live on ClinicalTrials.gov.